The REWIND Trial: Dulaglutide's Cardiovascular Evidence
TRIAL-000011
Part of the DietApp.com GLP-1 Trial Database, a comprehensive, regularly reviewed resource.
What It Is
REWIND, Researching Cardiovascular Events with a Weekly Incretin in Diabetes, is the trial that established dulaglutide's (Trulicity's) cardiovascular risk reduction indication. It enrolled 9,901 adults age 50 and older with type 2 diabetes across 24 countries, with a median follow-up of 5.4 years, the longest cardiovascular outcomes trial conducted in the GLP-1 class.
Key Results
Dulaglutide reduced major adverse cardiovascular events by a hazard ratio of 0.88, a 12% relative reduction, compared to placebo. The trial also showed durable reductions in A1C, body weight, and systolic blood pressure sustained over the full follow-up period. All-cause mortality did not differ significantly between groups.
Why This Trial Was Genuinely Different
REWIND was notable for enrolling a majority, 69%, of participants with no prior history of cardiovascular disease at enrollment, unlike most earlier GLP-1 cardiovascular trials, which focused on people who already had established cardiovascular disease. This makes REWIND meaningful evidence for primary prevention, using the medication before a cardiovascular event has occurred, not just secondary prevention after one.
A Real Tradeoff Worth Knowing
Gastrointestinal side effects were reported significantly more often in the dulaglutide group than placebo, 47.4% versus 34.1%, consistent with the GI side effect pattern seen across the GLP-1 class generally.
References
- Gerstein HC et al., REWIND Trial, The Lancet 2019
- Trulicity: Cardiovascular Outcomes, REWIND Trial Summary
- ADA Meeting News: REWIND Trial Reporting
Related Resources
Related Articles
- The LEADER Trial
- The EXSCEL Trial
- Trulicity vs. Ozempic
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Download DietApp.com to track your own progress alongside the evidence behind your treatment.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
Last medically reviewed and updated: July 11, 2026.
rewind-trial-dulaglutide